According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...
Only one in every six million people have the Rh null blood type. Now researchers are trying to grow it in the laboratory in ...
The market is driven by advancements in gene therapy, stem cell-based treatments, and increasing investment in rare diseases. Despite high costs, the market for these innovative treatments is growing, ...
AgroNetica, a leader in applying CRISPR technology for cacao, today unveils its revolutionary "super-cacao" project. While other companies focus on solving individual problems in Chocolate, AgroNetica ...
Constative on MSN
20 Ideas So Good They Won a Nobel
Since 1901, the Nobel Prize has honored ideas that changed the way we live. From discoveries that made headlines to ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...
Good evening, and welcome to Dyadic International's Q3 2025 Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, November 12, 2025. I would now like to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback